Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even Conference call to be held today, March 9, ...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer ...

U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in ...

ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline early commercial progress for neffy, its needle-free epinephrine option for ...

New car financing is available for under 4% APR for borrowers with high credit scores Written By Written by Staff Senior Editor, Buy Side Miranda Marquit is a staff senior personal finance editor for ...

ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and plans for sales force expansion amidst challenges in prescriber workflows and market penetration.

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...